Slide 1: Exchange intimation letter for earnings presentation
30th May, 2021 To, To, BSE Limited, The Manager, 25, P. J. Towers, Listing Department, Dalal Street, National Stock Exchange of India Ltd., Mumbai – 400 001 Exchange Plaza, Bandra Kurla Complex, Ref: Company Scrip Code: 532834 Bandra (East), Mumbai‐ 400051 Ref: Symbol: CAMLINFINE || Series: EQ Sub:
Slide 2: Earnings Presentation FY21 / Q4-FY21
EARNINGS PRESENTATION FY21 / Q4-FY21
Slide 3: Snapshot
Snapshot One of the few vertically and backward Leading Manufacturers of Antioxidants in the 3rd largest producer of Vanillin in the world integrated players world with more than 30 years of experience Serving more than 80 countries with over Preferred Partner for manufacturing customized Strategic
Slide 4: About the Company
About the Company • In 2006, Camlin Fine Sciences Limited (CFS) was formed after de-merging (mirror Total Operational Revenue (INR Mn) shareholding) the fine chemical business from Camlin Ltd. 11,871 • The Company has over 30 years of experience providing innovative solutions with a 10,491 competiti
Slide 5: FY21 / Q4-FY21 Financial Overview
FY21 / Q4-FY21 FINANCIAL OVERVIEW
Slide 6: FY21 / Q4-FY21 Financial Highlights
FY21 / Q4-FY21 Financial Highlights Q4-FY21 Financial Highlights (Consolidated): Q4-FY21 Financial Highlights (Standalone): INR 504 Mn INR 513 Mn INR 157 Mn INR 207 Mn INR 196 Mn INR 21 Mn EBITDA Adjusted EBITDA PAT EBITDA Adjusted EBITDA PAT INR 3,266 Mn INR 1,685 Mn Total Revenue Total Revenue 15.
Slide 7: Operational Highlights (Consolidated)
Operational Highlights (Consolidated) Quarter: • Operating revenue grew buoyed by the sustained growth and in spite of restriction of manufacture of Vanillin in Chinese facility • Dahej Diphenol Plant achieved 65% capacity utilisation in the quarter • Output being balanced to suit business needs wit
Slide 8: Q4-FY21 Consolidated Income Statement (Ind-AS)
Q4-FY21 Consolidated Income Statement (Ind-AS) Income Statement (INR Mn) Q4-FY21 Q3-FY21 Q-o-Q Q4-FY20 Y-o-Y Operational Revenue 3,266 2,979 9.6% 2,929 11.5% Total Expenses 2,762 2,511 10.0% 2,586 6.8% Operational EBITDA 504 468 7.7% 343 46.9% Operational EBITDA Margins (%) 15.43% 15.71% (28) Bps 11
Slide 9: FY21 Consolidated Income Statement (Ind-AS)
FY21 Consolidated Income Statement (Ind-AS) Income Statement (Mn) FY21 FY20 Y-o-Y Operational Revenue 11,871 10,491 13.2% Total Expenses 10,052 9,184 9.5% Operational EBITDA 1,819 1,307 39.2% Operational EBITDA Margins (%) 15.32% 12.46% 286 Bps Adjusted EBITDA* 1,968 1,307 50.6% Adjusted EBITDA Marg
Slide 10: Consolidated Balance Sheet
Consolidated Balance Sheet PARTICULARS (INR Mn) FY20 FY21 PARTICULARS (INR Mn) FY20 FY21 Non-Current Assets 5,591 6,869 EQUITY 4,601 7,131 a) Property, Plant and Equipment 2,034 4,818 a) Equity Share Capital 121 127 b) Capital Work In Progress 1,761 237 b) Other Equity 3,910 6,307 c) Right-Of-Use As
Slide 11: Q4-FY21 Standalone Income Statement (Ind-AS)
Q4-FY21 Standalone Income Statement (Ind-AS) Income Statement (Mn) Q4-FY21 Q3-FY21 Q-o-Q Q4-FY20 Y-o-Y Operational Revenue 1,685 1,636 3.0% 1,395 20.8% Total Expenses 1,488 1,457 1.4% 1,256 17.7% Operational EBITDA 197 179 15.6% 139 48.9% Operational EBITDA Margins (%) 11.63% 10.94% 134 Bps 9.96% 23
Slide 12: FY21 Standalone Income Statement (Ind-AS)
FY21 Standalone Income Statement (Ind-AS) Income Statement (Mn) FY21 FY20 Y-o-Y Operational Revenue 6,000 5,798 3.5% Total Expenses 5,382 5,201 3.5% Operational EBITDA 618 597 3.5% Operational EBITDA Margins (%) 10.30% 10.30% NA Adjusted EBITDA* 706 597 18.26% Adjusted EBITDA Margins (%) 11.77% 10.3
Slide 13: Standalone Balance Sheet
Standalone Balance Sheet Particulars (INR Mn) FY20 FY21 Particulars (INR Mn) FY20 FY21 EQUITY 3,768 4,646 Non-Current Assets 3,802 4,087 a) Equity Share Capital 121 127 a) Property, Plant and Equipment 686 2,457 b) Capital Work In Progress 1,742 184 b) Other Equity 3,647 4,519 c) Right-Of-Use Assets
Slide 14: Country Overview
COUNTRY OVERVIEW
Slide 15: Country Wise Quarterly Performance
Country Wise Quarterly Performance CFS India CFS Mexico CFS Europe Quarterly Operational 1,685 Revenue (INR Mn) 1,636 748 710 996 695 1,395 739 697 Q4-FY20 Q3-FY21 Q4-FY21 Q4-FY20 Q3-FY21 Q4-FY21 Q4-FY20 Q3-FY21 Q4-FY21 CFS Brazil CFS Wanglong CFS North America Quarterly Operational 218 570 Revenue
Slide 16: Country Wise Yearly Performance
Country Wise Yearly Performance CFS India CFS Mexico CFS Europe Operational Revenue 2,735 3,762 5,798 6,000 2,571 3,296 5,481 3,091 2,172 2,771 (INR Mn) 4,050 1,642 2,216 3,376 1,210 FY17 FY18 FY19 FY20 FY21 FY17 FY18 FY19 FY20 FY21 FY17 FY18 FY19 FY20 FY21 CFS Brazil CFS Wanglong CFS North America
Slide 17: Historical Financial Overview
HISTORICAL FINANCIAL OVERVIEW
Slide 18: Historical Standalone Income Statement
Historical Standalone Income Statement Particulars (INR Mn) FY19 FY20 FY21 Operational Income 5,481 5,798 6,000 Total Expenses 5,182 5,201 5,382 EBITDA 299 597 618 EBITDA Margin 5.46% 10.30% 10.30% Depreciation 91 113 193 Finance Cost 203 281 325 Other Income 137 241 55 Exceptional Items - 31 5 PBT
Slide 19: Historical Consolidated Income Statement
Historical Consolidated Income Statement PARTICULARS (INR Mn) FY19 FY20 FY21 Operational Income 8,922 10,491 11,871 Total Expenses 8,235 9,184 10,052 EBITDA 687 1,307 1,819 EBITDA Margin 7.70% 12.46% 15.32% Depreciation 290 328 443 Finance Cost 367 431 375 Other Income 138 34 50 Income from Associat
Slide 20: Consolidated Financial Highlights
Consolidated Financial Highlights Operational Revenue (INR Mn) EBITDA (INR Mn) & EBITDA Margin (%) 14,000 11,871 2,100 15.32% 18.00% 12,000 10,491 1,800 16.00% 12.46% 14.00% 10,000 8,922 1,500 1,819 7,228 12.00% 8,000 1,200 7.70% 1,307 10.00% 5,469 8.00% 6,000 900 5.16% 4,000 600 6.00% 1.74% 687 4.0
Slide 21: Capital Markets
Capital Markets 300% 250% 200% 150% 100% 50% 0% -50% Apr-20 May-20 Jun-20 Jul-20 Aug-20 Sep-20 Oct-20 Nov-20 Dec-20 Jan-21 Feb-21 Mar-21 Sensex Camlin Price Data (31st March, 2021) INR Shareholding Pattern as on 31st March, 2021 Face Value 1.0 Promoters 21.62% Market Price 139.8 52 Week H/L 160.7/35
Slide 22: Disclaimer
Disclaimer Camlin Fine Sciences Limited No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all e